- Home
- EPC vs AUPH Comparison
EPC vs AUPH Comparison
Compare EPC & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPC
- AUPH
- Stock Information
- Founded
- EPC 1999
- AUPH 1993
- Country
- EPC United States
- AUPH Canada
- Employees
- EPC N/A
- AUPH N/A
- Industry
- EPC Package Goods/Cosmetics
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- EPC Consumer Discretionary
- AUPH Health Care
- Exchange
- EPC Nasdaq
- AUPH Nasdaq
- Market Cap
- EPC 1.4B
- AUPH 1.4B
- IPO Year
- EPC 2000
- AUPH 1999
- Fundamental
- Price
- EPC $20.25
- AUPH $11.74
- Analyst Decision
- EPC Buy
- AUPH Strong Buy
- Analyst Count
- EPC 7
- AUPH 2
- Target Price
- EPC $28.29
- AUPH $13.00
- AVG Volume (30 Days)
- EPC 763.5K
- AUPH 1.9M
- Earning Date
- EPC 11-06-2025
- AUPH 11-06-2025
- Dividend Yield
- EPC 2.96%
- AUPH N/A
- EPS Growth
- EPC N/A
- AUPH N/A
- EPS
- EPC 1.34
- AUPH 0.42
- Revenue
- EPC $2,203,900,000.00
- AUPH $260,111,000.00
- Revenue This Year
- EPC N/A
- AUPH $17.33
- Revenue Next Year
- EPC $2.32
- AUPH $14.31
- P/E Ratio
- EPC $15.12
- AUPH $27.86
- Revenue Growth
- EPC N/A
- AUPH 25.59
- 52 Week Low
- EPC $19.13
- AUPH $6.55
- 52 Week High
- EPC $38.45
- AUPH $13.54
- Technical
- Relative Strength Index (RSI)
- EPC 39.91
- AUPH 46.50
- Support Level
- EPC $19.87
- AUPH $11.18
- Resistance Level
- EPC $21.05
- AUPH $11.70
- Average True Range (ATR)
- EPC 0.60
- AUPH 0.66
- MACD
- EPC 0.09
- AUPH -0.18
- Stochastic Oscillator
- EPC 54.44
- AUPH 42.50
About EPC Edgewell Personal Care Company
Edgewell Personal Care Co is a personal-care company. The operating segments of the company include Wet Shave, Sun and Skin Care and Feminine Care. Some of the brands offered by the company include Edge, Skintimate, Personna, Schick, Carefree, Playtex, Banana Boat and Hawaiian Tropic. It derives a majority of its revenue from the United States.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.